Stock-PR.com Friday Hot Stock Alerts Jan. 21, 2010 - Stock-PR's Blogs

Mywallst

WallSt.net

WallSt TV

WallSt Radio

Jan
21

Stock-PR.com Friday Hot Stock Alerts Jan. 21, 2010

Posted: 1 month(s) and 27 days(s) ago |

0 Comment(s) | Rating: 0

Posted by: Stock-PR

Stock-PR Reporting

stockpr_logo-site

FREE Daily Stock Alerts From Stock-PR.com

________________________________________

January 21, 2010 Aastrom Biosciences, Inc. (ASTM) Recent News: Aastrom Biosciences Announces Closing of Unit Offering ASTM announced the closing of its previously announced underwritten public offering from which the Company received approximately $12.4 million in net proceeds from the sale of the units. Chief Executive Officer of Aastrom, Tim Mayleben said, "This financing further strengthens our balance sheet and provides us with funding essential to completing our ongoing Phase II clinical trials. About Aastrom Biosciences, Inc. Aastrom is a leader in regenerative medicine developing personalized cell products for the treatment of severe, chronic cardiovascular diseases. The Company's proprietary Tissue Repair Cell (TRC) technology expands the numbers of stem and early progenitor cells from a small amount of bone marrow collected from the patient. Bone marrow provides a rich source of diverse cell populations, is easily accessible and allows Aastrom to produce a personalized treatment for site-specific delivery to the patient's diseased tissues. Aastrom has safely treated more than 375 patients in various clinical trials over 10 years. The Company is currently conducting a Phase II cardiac regeneration clinical trial (the IMPACT-DCM trial) in patients with dilated cardiomyopathy (DCM - severe chronic heart failure) and a Phase IIb vascular regeneration clinical trial (the RESTORE-CLI trial) in patients with critical limb ischemia (CLI - the most severe form of peripheral arterial disease). Aastrom has also recently announced that the Company will initiate its U.S. Phase II clinical trial to evaluate the catheter delivery of CRCs for the treatment of DCM. For more information, visit Aastrom's website at www.aastrom.com. ____________________________________________________ Power 3 Medical Products Inc. (PWRM.OB) A common thread links these illnesses that together affect millions of Americans: there are no cures, nor are there effective treatments that consistently slow or stop the relentless course of these devastating neurodegenerative diseases. PWRM has completed proof-of-concept and clinical validation studies, with results exceeding expectations of their The NuroPro Test. The NuroPro Blood Test is Power3's diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease . Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms. About Power3 Medical Products, Inc. Power3 Medical Products, http://www.Power3Medical.com, is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas and continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer's, and Parkinson's diseases, breast cancer, and drug resistance. For more information visit, http://www.Power3Medical.com

____________________________________

Published by Editor in Chief

Christina Collins

ccollins@crownequityholdings.com

5440 W. Sahara Ave. Suite 205

Las Vegas, Nevada 89146 Toll Free: 877 854-6797 Phone: 702 448-1543 Fax: 702 479-7151

***Be Sure To Visit* *stock-pr.ning.com***

******Advertisement******

promolinks23

********************************

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and diseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.